BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, Tardon A, Shete S, Schabath MB, Teare MD, Le Marchand L, Zhang ZF, Field JK, Brenner H, Diao N, Xie J, Kohno T, Harris CC, Wenzlaff AS, Fernandez-Tardon G, Ye Y, Taylor F, Wilkens LR, Davies M, Liu Y, Barnett MJ, Goodman GE, Morgenstern H, Holleczek B, Thomas S, Brown MC, Hung RJ, Xu W, Liu G. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer 2021;152:58-65. [PMID: 33352384 DOI: 10.1016/j.lungcan.2020.11.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Evcil FY, Önal Ö, Özkan EE. The Effect of Body Mass Index on Survival in Lung Cancer. Nutr Cancer 2023;75:857-66. [PMID: 36573347 DOI: 10.1080/01635581.2022.2159045] [Reference Citation Analysis]
2 Hawrysz I, Wadolowska L, Slowinska MA, Czerwinska A, Golota JJ. Lung Cancer Risk in Men and Compliance with the 2018 WCRF/AICR Cancer Prevention Recommendations. Nutrients 2022;14. [PMID: 36296978 DOI: 10.3390/nu14204295] [Reference Citation Analysis]
3 Wang F, He T, Wang G, Han T, Yao Z. Association of triglyceride glucose-body mass index with non-small cell lung cancer risk: A case-control study on Chinese adults. Front Nutr 2022;9:1004179. [PMID: 36313086 DOI: 10.3389/fnut.2022.1004179] [Reference Citation Analysis]
4 Wang F, Li Y, Li Z, Zou Z, Lu Y, Xu C, Zhao Z, Wang H, Wang Y, Guo S, Jin L, Wang J, Li Q, Jiang G, Xia F, Shen B, Wu J. Prognostic value of GPC5 polymorphism rs2352028 and clinical characteristics in Chinese lung cancer patients. Future Oncol 2022. [PMID: 36165234 DOI: 10.2217/fon-2022-0319] [Reference Citation Analysis]
5 Yuan Z, Cheng Y, Han J, Wang D, Dong H, Shi Y, Poulsen KL, Fan X, Zhao J. Association between metabolic overweight/obesity phenotypes and readmission risk in patients with lung cancer: A retrospective cohort study. EClinicalMedicine 2022;51:101577. [PMID: 35898319 DOI: 10.1016/j.eclinm.2022.101577] [Reference Citation Analysis]
6 Shao F, Chen Y, Xu H, Chen X, Zhou J, Wu Y, Tang Y, Wang Z, Zhang R, Lange T, Ma H, Hu Z, Shen H, Christiani DC, Chen F, Zhao Y, You D. Metabolic Obesity Phenotypes and Risk of Lung Cancer: A Prospective Cohort Study of 450,482 UK Biobank Participants. Nutrients 2022;14:3370. [DOI: 10.3390/nu14163370] [Reference Citation Analysis]
7 Rolfo C, Hess LM, Jen MH, Peterson P, Li X, Liu H, Lai Y, Sugihara T, Kiiskinen U, Vickers A, Summers Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open 2022;7:100551. [PMID: 35930972 DOI: 10.1016/j.esmoop.2022.100551] [Reference Citation Analysis]
8 Schmid S, Jiang M, Brown MC, Fares A, Garcia M, Soriano J, Dong M, Thomas S, Kohno T, Leal LF, Diao N, Xie J, Wang Z, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Wenzlaff AS, Harris CC, Caporaso NE, Ma H, Fernandez-Tardon G, Barnett MJ, Goodman G, Davies MPA, Pérez-Ríos M, Taylor F, Duell EJ, Schoettker B, Brenner H, Andrew A, Cox A, Ruano-Ravina A, Field JK, Marchand LL, Wang Y, Chen C, Tardon A, Shete S, Schabath MB, Shen H, Landi MT, Ryan BM, Schwartz AG, Qi L, Sakoda LC, Brennan P, Yang P, Zhang J, Christiani DC, Reis RM, Shiraishi K, Hung RJ, Xu W, Liu G. Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiol Biomarkers Prev 2022;31:679-87. [PMID: 35027437 DOI: 10.1158/1055-9965.EPI-21-0747] [Reference Citation Analysis]
9 Schussler O, Bobbio A, Dermine H, Lupo A, Damotte D, Lecarpentier Y, Alifano M. Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters. Cancers (Basel) 2022;14:874. [PMID: 35205621 DOI: 10.3390/cancers14040874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xuan J, Peng J, Wang S, Cai Y. Prognostic significance of Naples prognostic score in non-small-cell lung cancer patients with brain metastases. Future Oncol 2022. [PMID: 35107367 DOI: 10.2217/fon-2021-1530] [Reference Citation Analysis]
11 Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma. NPJ Precis Oncol 2022;6:8. [PMID: 35087143 DOI: 10.1038/s41698-021-00248-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer 2021;21:1308. [PMID: 34876060 DOI: 10.1186/s12885-021-09034-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Nizam W, Yeo HL, Obeng-Gyasi S, Brock MV, Johnston FM. Disparities in Surgical Oncology: Management of Advanced Cancer. Ann Surg Oncol 2021. [PMID: 34268636 DOI: 10.1245/s10434-021-10275-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002349. [PMID: 34127546 DOI: 10.1136/jitc-2021-002349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Leitner BP, Ospanova S, Beisenbayeva A, Givechian KB, Politi K, Perry RJ. Multimodal Analysis Reveals Differential Immuno-Metabolic Features in Lung Squamous Cell Carcinoma and Adenocarcinoma.. [DOI: 10.1101/2021.05.09.443240] [Reference Citation Analysis]
16 Liu G, Brenner H, Chen C, Christiani D, Field JK, Hung R, Jie Z, Le Marchand L, Ryan B, Schabath MB, Schwartz AG, Shete S, Shiraishi K, Tardon A, Teare MD, Yang P, Zhang ZF, Xu W. A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?". Lung Cancer 2021;154:225-6. [PMID: 33726925 DOI: 10.1016/j.lungcan.2021.02.019] [Reference Citation Analysis]